BRCA1 and neoplasm: Finally, a retrospective real-world analysis of 445 mCRPC patients in the Flatiron Health–Foundation Medicine clinico-genomic database treated with single-agent PARP inhibitors showed that men with homozygous BRCA1/2 deletions derived the most durable benefit, with median time-to-next-treatment 19.4 vs. 9.0 months and OS of 19.4 vs. 14.7 months compared with other pathogenic BRCA variants, highlighting the need for tissue NGS or high-tumor-fraction (≥20%) ctDNA assays to detect these deep deletions [52].